Charles River Laboratories International (CRL) saw its stock draw attention after exceeding Q4 earnings and revenue forecasts and providing optimistic 2026 guidance. Despite recent share price declines, the company is considered undervalued by analysts and models, with a fair value of $215.73 against a last close of $163.52. This valuation is underpinned by strategic investments in diversification, automation, and digitalization, positioning CRL for future margin stability and growth in complex testing markets.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Assessing Charles River Laboratories (CRL) Valuation After Earnings Beat And 2026 Improvement Guidance
Charles River Laboratories International (CRL) saw its stock draw attention after exceeding Q4 earnings and revenue forecasts and providing optimistic 2026 guidance. Despite recent share price declines, the company is considered undervalued by analysts and models, with a fair value of $215.73 against a last close of $163.52. This valuation is underpinned by strategic investments in diversification, automation, and digitalization, positioning CRL for future margin stability and growth in complex testing markets.